Dihydrotestosterone

Dihydrotestosterone
Abbreviation	DHT
Molecular formula	C₁₉H₃₀O₂
Type	Steroid hormone (potent androgen; 5α-reduced metabolite of testosterone)
Administration	Topical (cream/gel is preferred), oral (less common), transdermal
Bioavailability	Topical: good absorption, favors androgenic pathway; Oral: less effective
Synonyms	5α-Dihydrotestosterone, Stanolone, Androstanolone
Source	Produced from testosterone via 5α-reductase enzyme (skin, prostate, hair follicles, liver); pharmaceutical: synthetic
Ray's verdict	Strongly positive in miniscule doses, the "safe" androgen, can't convert to estrogen,

Introduction

Dihydrotestosterone, commonly abbreviated as DHT or androstanolone, is the most potent endogenous androgen in the human body. It is a metabolite of testosterone and plays a crucial role in male sexual development, maturation, and overall health. Despite mainstream medicine's portrayal of DHT as a harmful hormone responsible for hair loss and prostate cancer, emerging research suggests it may actually be protective and beneficial across multiple organ systems.

DHT levels decline rapidly with aging, and DHT administration has been shown to restore vitality even in 90+ year old males. (Haidut, "Raising DHT Levels Even Only in the Brain Reverses Systemic Atherosclerosis") The totality of available studies suggests that testosterone is primarily a precursor to DHT, with DHT being responsible for both the male phenotype and optimal male health.

History/Etymology

The name "dihydrotestosterone" reflects its chemical relationship to testosterone: it is the "dihydro" (two additional hydrogen atoms) derivative of testosterone. DHT was first characterized in the mid-20th century as researchers explored androgen metabolism and the 5-alpha reductase pathway.

In the 1950s and 1960s, medicine recognized that DHT and related steroids had great potential for treating estrogen receptor-positive breast cancer. DHT was used clinically with remarkable success, achieving up to 80% cure rates. However, its strong virilizing effects in women led to the development of methylated derivatives like Proviron (1-alpha-methyl DHT) and Masteron (2-alpha-methyl DHT), which retained anti-estrogenic effects with less virilization.

Structure/Chemical properties

DHT has the molecular formula C19H30O2 and is classified as a fully saturated steroid. This saturation is particularly significant: saturated steroids tend to be androgenic, while unsaturated steroids tend to be estrogenic. The degree of unsaturation largely determines a steroid's respective strength as an androgen or estrogen. DHT, being fully saturated with no double bonds, is potently anti-estrogenic.

Key chemical characteristics:

• Non-aromatizable: Unlike testosterone, DHT cannot be converted to estrogen via the aromatase enzyme, making it inherently anti-estrogenic
• Potency: DHT is 2.5 to 10-fold more potent than testosterone at the androgen receptor in bioassays
• Systemic levels: Circulating levels of total DHT are about 1/10th the concentration of total testosterone, though local tissue concentrations can be up to 10 times higher in specific areas

Function/Mechanism of Action

DHT exerts its effects primarily through binding to and activating the androgen receptor (AR), where it displays significantly higher affinity than testosterone. It is the primary hormone responsible for:

1. Sexual differentiation and maturation: Development of male genitalia, deepening of voice, facial hair, body hair
2. Anti-estrogenic activity: DHT directly antagonizes estrogen at the receptor level and also inhibits aromatase
3. Anti-inflammatory effects: DHT demonstrates anti-inflammatory potency comparable to cortisol but without the metabolic side effects
4. Serotonin suppression: DHT inhibits tryptophan hydroxylase (TPH), the rate-limiting enzyme in serotonin synthesis
5. PI3 kinase/Akt activation: DHT activates PI3 kinase signaling, responsible for anti-apoptotic activities and cell survival

Notably, DHT is inactivated in muscle tissue by the enzyme 3-alpha hydroxysteroid dehydrogenase, converting it to the weak androgen 3-alpha-androstanediol. This explains why DHT drives sexual maturation but has minimal direct effects on muscle growth.

Medical uses/Effects

Stops aging of pancreatic beta-cells (anti-diabetic potential)

DHT dose-dependently inhibits the aging and dysfunction of pancreatic beta-cells (insulin-producing cells), with the highest doses completely stopping the senescence process. DHT demonstrates:

• Anti-oxidant protective capacity
• Significant reduction in stress-induced senescence markers
• Protection from H2O2-induced oxidative stress
• Increased SIRT1 expression (longevity-associated)
• Decreased p16 expression (aging marker)

The results suggest DHT may become viable therapy for conditions related to insulin dysfunction, essentially a treatment for various types of diabetes.

Prevents and may treat prostate cancer

Contrary to the mainstream "androgen hypothesis," multiple in vivo studies demonstrate that DHT does not cause prostate cancer and may actually prevent or treat it:

• In vivo studies found that higher doses of DHT completely prevented prostate cancer development while lower doses strongly reduced incidence
• Testosterone treatment actually increased prostate cancer incidence (due to aromatization to estrogen), while DHT-treated animals had healthy prostates
• Epidemiological data shows high DHT levels were positively correlated with lower risk of prostate cancer death (HR = 0.44)
• A study with massive DHT doses (70mg daily) found no ill effects and no increase in androgen levels inside the prostate
• Drostanolone (a DHT isomer) demonstrated therapeutic effects against prostate cancer, proving more potent than cisplatin chemotherapy

Ray has written that prostate cancer appears to be estrogen-driven and has suggested using testosterone as treatment to raise the androgen/estrogen ratio.

Estrogen causes prostate fibrosis/cancer; DHT prevents and reverses it

The myth that DHT causes prostate disease is increasingly discredited in basic research circles. A pivotal study demonstrated:

• Estradiol causes and promotes prostate fibrosis (a precursor to prostate cancer)
• DHT prevents estrogen's fibrotic effects on the prostate
• DHT reverses established fibrosis when estrogen was administered first
• A human equivalent dose of just 1-2mg DHT daily replicated these protective effects

Hair loss causation debunked

The DHT theory of baldness has significant problems:

Evidence against DHT as the cause:

• Bald men do not have higher testosterone or DHT levels than men with full hair. Studies conclude "bald men are no more masculine than those with good scalp hair growth"
• Increased serum concentrations of DHT were not correlated with advancing alopecia
• Studies examining balding scalps find elevated estrogen and prolactin alongside elevated DHT. Nobody has proven DHT alone causes hair loss.
• When examining the actual hormone situation of people with hair loss, "what you see is an excess of prolactin and cortisol in the people losing their hair, both men and women."

Evidence androgens promote hair growth:

• Testosterone was anabolic for hair growth in women with androgenic alopecia
• Topical testosterone administration regrew hair in older men (1965 study)
• Testosterone therapy (133mg over 28 months) reversed hair loss in women. Not a single woman receiving T therapy reported hair thinning despite blood T reaching 4 times higher than normal.
• Estrogen, not androgens, may cause baldness. Administration of estrogen antagonists restored hair back to normal levels in bald mice.
• Chronic stress via cortisol/estrogen/prolactin pathways is the main driver of hair loss. DHT robustly promoted hair growth in studies using cortisol-blocking interventions.

More in Hair loss/Androgenic Alopecia

Topical DHT has anti-aging effects on skin

An extensive 1967 study on 200+ individuals aged 57-88 demonstrated that topical testosterone (1%) cream had the most potent anti-aging effects on skin in both men and women, followed closely by 1% progesterone and 1% pregnenolone. Topical testosterone converts mostly into DHT, and the proposed mechanism is increased androgenic tone. Estradiol, by contrast, showed minimal effects.

A more recent study using topical DHEA (1-2% creams) demonstrated robust anti-aging effects via:

• 3-fold increase in androgen receptor expression
• Increased synthesis of DHT by the skin using DHEA as precursor
• No increase in estrogen receptor expression

Additional therapeutic applications

• Cardiovascular health: Declining DHT in aging is linked to cardiovascular disease. DHT administration (even only in the brain) reverses systemic atherosclerosis and associated inflammation.
• Multiple sclerosis: DHT completely reversed MS pathology in animal models by activating the neural androgen receptor
• Thyroid cancer: DHT may treat thyroid cancer at physiological concentrations (10 nM/L) by inducing G1 cell cycle arrest
• Chronic kidney disease: An aromatase inhibitor + DHT combination reversed kidney disease associated with diabetes

Unedited, undourced claims

• Causes prostate fibrosis/cancer? No , estrogen does; DHT prevents/reverses it

• Hair loss causation debunked, DHT is found elevated in balding scalps alongside elevated estrogen and prolactin; nobody has proven DHT alone causes hair loss; some studies show DHT and testosterone promote hair growth

Dosing

• For prostate protection: Human equivalent dose of 1-2mg daily
• For optimal androgenic effects: Studies suggest 5-8mg daily achieves optimal results. DHT is about 3-5 times more potent than testosterone, so this achieves similar effects to 25mg testosterone.
• For kidney disease/diabetes: Human equivalent dose approximately 5-10mg daily
• Ray Peat's recommendation: Ray has stated to not use more than 5-10mg testosterone daily; DHT would require proportionally less due to higher potency so miniscule doses about1-5mg
• Alternative via DHEA: 10-15mg DHEA daily reliably replenishes the DHT pool over time by raising DHT metabolite levels 2-3 fold

Ray has described DHT as "by far the best male steroid you can try" for frail people, and has been recommending it to people with kidney disease, prostate problems, and various cancers.

Ray's caution on DHT supplementation

While the research on DHT's protective effects is compelling, Ray Peat himself expressed significant reservations about supplementing it directly. His concern centered on the principle that downstream steroids carry more risk than upstream precursors.

The "downstream" problem

"The farther a substance is from its precursor material, the easier it is to cause unwanted effects when supplementing it."

DHT sits at the far end of the steroidogenic pathway, making it a "defining feature creating hormone" that can shift the entire system unpredictably.

Direct statements on DHT

When asked about DHT supplementation, Ray stated:

"In general, things like that are not to be messed with unless you have a very specific knowledge of a deficiency, because if you take a little too much, any of those defining feature creating hormones can change the whole system in an unpredictable way."

He recommended instead using vitamin D, DHEA, pregnenolone, and thyroid to increase DHT naturally. Only in serious conditions like breast cancer or prostate cancer did he consider DHT supplementation appropriate:

"In something like breast cancer or prostate cancer, it's one of the things that could give a big push to the system if you're wanting to interrupt the process."

DHT Is not "male progesterone"

When Georgi Dinkov asked Ray if DHT was the male equivalent of progesterone, He firmly rejected the idea. He said pregnenolone should come first, then DHEA if more androgenic support is needed. The concern was that a strong androgen like DHT could throw off neurosteroid balance.

Preferred approach: upstream support

Ray consistently advocated for upstream precursors over downstream hormones:

"Yes, pure testosterone on the skin is safe if the diet and thyroid function are good, but it's better to try supplements of pregnenolone first, and then DHEA, to normalize the testosterone production."

For raising androgens safely, Ray recommended: pregnenolone, DHEA (5-10mg), good thyroid function, aspirin, and vitamin D as protective factors against aromatization.

Administration routes

• Topical is generally preferred for androgens because skin has high 5-AR expression, favoring conversion to DHT over estrogen. Bioavailability is around 33-70% depending on solvent, and effects last longer than oral. Navel application approaches 80% absorption, rivaling intravenous.
• Sublingual/buccal (lips, tongue, gums) provides rapid absorption directly into circulation, bypassing first-pass liver metabolism. Ray noted that 1mg testosterone "is very well absorbed by the lips or the tongue" with strong effects. This route avoids liver aromatase.
• Oral has the poorest bioavailability (around 3% for DHEA) and passes through the liver where aromatase expression is high, increasing estrogen conversion. The androgenic:estrogenic ratio drops to 2:1 compared to 10:1 for topical.
• Injections (subcutaneous pellets or intramuscular) have 100% bioavailability but bypass skin's 5-AR, resulting in more estrogenic conversion (3:1 ratio). Ray considered testosterone injections risky, noting people commonly inject "30 or 50 milligrams per week, which is several times what a teenage boy would be making" and "it's all going to be going towards estrogen." He also warned that injectable esters typically use toxic solvents.

Important note on esters: Bioidentical DHT appears protective, but esterified forms (DHT propionate, DHT benzoate) promoted tumor development in some studies. This may relate to the solvents used (benzyl benzoate) rather than the DHT itself.

Brands and sources

AlphaGels

Pandalabs

Side/Adverse effects

DHT is generally well-tolerated, especially at physiological doses, (ideally less, around 1mg).

Potential considerations:

In women:

• Shouldn't be supplemented unless directly treating a serious condition
• Virilizing effects at higher doses: facial hair growth, body hair, voice thickening
• This led to development of methylated derivatives (Proviron, Masteron) for therapeutic use without virilization

General:

• One study in eugonadal men noted transient feelings of congestion and irritability during first 3-4 weeks of supraphysiological DHT administration, which then resolved
• No ill effects observed even at massive doses (70mg daily) in prostate studies
• Even massive doses (human equivalent 500mg+ single dose) showed beneficial effects in beta-cell studies, contradicting claims that DHT harms in any amount